Chardan Capital analyst Keay Nakae reiterated a Buy rating on Arrowhead Research (NASDAQ: ARWR) on August 8 and set a price target of $17.50. The company’s shares closed on Friday at $16.89, close to its 52-week high of $17.50.
According to TipRanks.com, Nakae has currently no stars on a ranking scale of 0-5 stars, with an average return of -19.3% and a 28.8% success rate. Nakae covers the Healthcare sector, focusing on stocks such as Arbutus Biopharma Corporation, Arcturus Therapeutics Ltd, and Dicerna Pharma.
Arrowhead Research has an analyst consensus of Strong Buy, with a price target consensus of $19.83, a 17.4% upside from current levels. In a report issued on August 1, Cantor Fitzgerald also initiated coverage with a Buy rating on the stock with a $13 price target.
.
See today’s analyst top recommended stocks >>
Based on Arrowhead Research’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $15.61 million. In comparison, last year the company had a GAAP net loss of $5.52 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Arrowhead Pharmaceuticals, Inc. engages as a biopharmaceutical company developing targeted RNAi therapeutics. Its pipeline includes clinical programs in chronic hepatitis B virus and partner based programs in obesity and oncology. The company was founded by R. Bruce Stewart in 1989 and is headquartered in Pasadena, CA.
Read More on ARWR:
